Cerus/$CERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Ticker
$CERS
Sector
Primary listing
Employees
268
Headquarters
Website
Cerus Metrics
BasicAdvanced
$521m
-
-$0.05
1.63
-
Price and volume
Market cap
$521m
Beta
1.63
52-week high
$3.15
52-week low
$1.15
Average daily volume
2.4m
Financial strength
Current ratio
1.633
Quick ratio
1.022
Long term debt to equity
61.238
Total debt to equity
142.574
Interest coverage (TTM)
-0.31%
Profitability
EBITDA (TTM)
-1.616
Gross margin (TTM)
52.99%
Net profit margin (TTM)
-4.41%
Operating margin (TTM)
-1.47%
Effective tax rate (TTM)
-4.03%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
-0.93%
Return on equity (TTM)
-15.37%
Valuation
Price to revenue (TTM)
2.31
Price to book
7.71
Price to tangible book (TTM)
7.86
Price to free cash flow (TTM)
-410.678
Free cash flow yield (TTM)
-0.24%
Free cash flow per share (TTM)
-0.006
Growth
Revenue change (TTM)
16.97%
Earnings per share change (TTM)
-51.31%
3-year revenue growth (CAGR)
11.65%
10-year revenue growth (CAGR)
20.28%
3-year earnings per share growth (CAGR)
-42.41%
10-year earnings per share growth (CAGR)
-22.66%
What the Analysts think about Cerus
Analyst ratings (Buy, Hold, Sell) for Cerus stock.
Cerus Financial Performance
Revenues and expenses
Cerus Earnings Performance
Company profitability
Cerus News
AllArticlesVideos
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Business Wire·7 days ago
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Business Wire·2 weeks ago
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs